S&P 500   4,291.55 (-1.06%)
DOW   33,722.18 (-0.84%)
QQQ   355.51 (-1.14%)
AAPL   172.93 (-1.79%)
MSFT   312.27 (-1.66%)
META   299.36 (-0.49%)
GOOGL   128.02 (-2.36%)
AMZN   127.64 (-2.77%)
TSLA   247.22 (+0.09%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.13 (-1.25%)
AMD   96.20 (-1.21%)
T   15.05 (-0.07%)
F   12.55 (-0.24%)
MU   68.18 (-0.58%)
CGC   0.94 (-0.40%)
GE   110.10 (-1.45%)
DIS   80.50 (-0.63%)
AMC   8.11 (-0.37%)
PFE   32.90 (-0.24%)
PYPL   59.11 (+0.42%)
NFLX   381.67 (-0.81%)
S&P 500   4,291.55 (-1.06%)
DOW   33,722.18 (-0.84%)
QQQ   355.51 (-1.14%)
AAPL   172.93 (-1.79%)
MSFT   312.27 (-1.66%)
META   299.36 (-0.49%)
GOOGL   128.02 (-2.36%)
AMZN   127.64 (-2.77%)
TSLA   247.22 (+0.09%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.13 (-1.25%)
AMD   96.20 (-1.21%)
T   15.05 (-0.07%)
F   12.55 (-0.24%)
MU   68.18 (-0.58%)
CGC   0.94 (-0.40%)
GE   110.10 (-1.45%)
DIS   80.50 (-0.63%)
AMC   8.11 (-0.37%)
PFE   32.90 (-0.24%)
PYPL   59.11 (+0.42%)
NFLX   381.67 (-0.81%)
S&P 500   4,291.55 (-1.06%)
DOW   33,722.18 (-0.84%)
QQQ   355.51 (-1.14%)
AAPL   172.93 (-1.79%)
MSFT   312.27 (-1.66%)
META   299.36 (-0.49%)
GOOGL   128.02 (-2.36%)
AMZN   127.64 (-2.77%)
TSLA   247.22 (+0.09%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.13 (-1.25%)
AMD   96.20 (-1.21%)
T   15.05 (-0.07%)
F   12.55 (-0.24%)
MU   68.18 (-0.58%)
CGC   0.94 (-0.40%)
GE   110.10 (-1.45%)
DIS   80.50 (-0.63%)
AMC   8.11 (-0.37%)
PFE   32.90 (-0.24%)
PYPL   59.11 (+0.42%)
NFLX   381.67 (-0.81%)
S&P 500   4,291.55 (-1.06%)
DOW   33,722.18 (-0.84%)
QQQ   355.51 (-1.14%)
AAPL   172.93 (-1.79%)
MSFT   312.27 (-1.66%)
META   299.36 (-0.49%)
GOOGL   128.02 (-2.36%)
AMZN   127.64 (-2.77%)
TSLA   247.22 (+0.09%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.13 (-1.25%)
AMD   96.20 (-1.21%)
T   15.05 (-0.07%)
F   12.55 (-0.24%)
MU   68.18 (-0.58%)
CGC   0.94 (-0.40%)
GE   110.10 (-1.45%)
DIS   80.50 (-0.63%)
AMC   8.11 (-0.37%)
PFE   32.90 (-0.24%)
PYPL   59.11 (+0.42%)
NFLX   381.67 (-0.81%)
NASDAQ:RZLT

Rezolute (RZLT) Stock Forecast, Price & News

$1.37
+0.04 (+3.01%)
(As of 12:32 PM ET)
Compare
Today's Range
$1.33
$1.43
50-Day Range
$1.33
$2.04
52-Week Range
$1.30
$2.97
Volume
35,066 shs
Average Volume
30,408 shs
Market Capitalization
$50.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Rezolute MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
529.4% Upside
$9.00 Price Target
Short Interest
Bearish
0.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of Rezolute in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$9,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.17) to ($1.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

344th out of 961 stocks

Pharmaceutical Preparations Industry

147th out of 454 stocks


RZLT stock logo

About Rezolute (NASDAQ:RZLT) Stock

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

RZLT Price History

RZLT Stock News Headlines

U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Rezolute (NASDAQ:RZLT) Given Overweight Rating at Cantor Fitzgerald
Rezolute's (RZLT) Buy Rating Reiterated at HC Wainwright
Expert Ratings for Rezolute
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
What 4 Analyst Ratings Have To Say About Rezolute
JMP Securities Reaffirms Their Buy Rating on Rezolute (RZLT)
JMP Securities Remains a Buy on Rezolute (RZLT)
JMP Securities Sticks to Their Buy Rating for Rezolute (RZLT)
See More Headlines
Receive RZLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter.

RZLT Company Calendar

Last Earnings
9/14/2023
Today
9/26/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RZLT
Fax
N/A
Employees
47
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+576.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-51,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.15 per share

Miscellaneous

Free Float
30,125,000
Market Cap
$48.98 million
Optionable
Not Optionable
Beta
2.16
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Nevan Charles Elam J.D. (Age 56)
    Founder, CEO & Acting Chairman
    Comp: $918.34k
  • Dr. Brian Kenneth Roberts M.D. (Age 48)
    Chief Medical Officer
    Comp: $575.43k
  • Mr. Chris Milks
    VP & Head of Fin.
  • Dr. Davelyn Eaves Hood M.B.A.
    M.D., Director and Head of Scientific & Patient Affairs
  • Mr. Michael R. Deperro
    Sr. VP & Head of Corp. Devel.
  • Mr. Michael Covarrubias
    Sr. VP & Head of Program & Portfolio Management
  • Dr. Raj Agrawal M.D.
    VP & Head of Ophthalmological Clinical Devel.
  • Ms. Robyn Sweinhart
    VP & Head of Quality
  • Ms. Erin O'Boyle
    Sr. VP & Head of Clinical Operations
  • Ms. Susan Stewart J.D. (Age 62)
    L.L.M., Chief Regulatory Officer













RZLT Stock - Frequently Asked Questions

Should I buy or sell Rezolute stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RZLT shares.
View RZLT analyst ratings
or view top-rated stocks.

What is Rezolute's stock price forecast for 2023?

3 brokers have issued 12-month price targets for Rezolute's shares. Their RZLT share price forecasts range from $5.00 to $14.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 576.7% from the stock's current price.
View analysts price targets for RZLT
or view top-rated stocks among Wall Street analysts.

How have RZLT shares performed in 2023?

Rezolute's stock was trading at $2.07 at the beginning of 2023. Since then, RZLT shares have decreased by 35.7% and is now trading at $1.33.
View the best growth stocks for 2023 here
.

When is Rezolute's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our RZLT earnings forecast
.

How were Rezolute's earnings last quarter?

Rezolute, Inc. (NASDAQ:RZLT) announced its quarterly earnings data on Thursday, September, 14th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.11.

What other stocks do shareholders of Rezolute own?
What is Rezolute's stock symbol?

Rezolute trades on the NASDAQ under the ticker symbol "RZLT."

Who are Rezolute's major shareholders?

Rezolute's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (8.34%), Stonepine Capital Management LLC (8.34%), Caxton Corp (3.58%), Silverarc Capital Management LLC (1.36%), Citadel Advisors LLC (0.89%) and Northern Trust Corp (0.23%). Insiders that own company stock include Brian Kenneth Roberts, Genexine Inc and Gil M Labrucherie.
View institutional ownership trends
.

How do I buy shares of Rezolute?

Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rezolute's stock price today?

One share of RZLT stock can currently be purchased for approximately $1.33.

How much money does Rezolute make?

Rezolute (NASDAQ:RZLT) has a market capitalization of $48.98 million. The company earns $-51,790,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How can I contact Rezolute?

Rezolute's mailing address is 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065. The official website for the company is www.rezolutebio.com. The company can be reached via phone at (650) 206-4507 or via email at investor-relations@rezolutebio.com.

This page (NASDAQ:RZLT) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -